NCT02518607View on ClinicalTrials.gov

Safety, Blood Levels and Effects of MGB-BP-3

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions
Healthy
Interventions
DRUG

MGB-BP-3

Treatment of CDI

OTHER

Placebo

Placebo

Sponsors
All Listed Sponsors
collaborator

Hammersmith Medicines Research

OTHER

collaborator

Innovate UK

OTHER_GOV

collaborator

Cambridge Regulatory Services

UNKNOWN

collaborator

Phases Clinical Research Limited

UNKNOWN

collaborator

Synlab Services

UNKNOWN

collaborator

Viapath

UNKNOWN

collaborator

Analytical Services International Limited

UNKNOWN

lead

MGB Biopharma Limited

INDUSTRY